{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:47:06Z","timestamp":1785757626639,"version":"3.56.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52495014"],"award-info":[{"award-number":["52495014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U25A20146"],"award-info":[{"award-number":["U25A20146"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32571604"],"award-info":[{"award-number":["32571604"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-74006-y","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:31:56Z","timestamp":1781775116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineering a dual-antigen mRNA vaccine to restore immune control in chronic hepatitis B"],"prefix":"10.1038","volume":"17","author":[{"given":"Baowen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6046-2934","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4386-3992","authenticated-orcid":false,"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"74006_CR1","doi-asserted-by":"publisher","first-page":"104992","DOI":"10.1016\/j.phrs.2020.104992","volume":"159","author":"L Jia","year":"2020","unstructured":"Jia, L., Gao, Y., He, Y., Hooper, J. D. & Yang, P. HBV induced hepatocellular carcinoma and related potential immunotherapy. Pharmacol. Res. 159, 104992 (2020).","journal-title":"Pharmacol. Res."},{"key":"74006_CR2","doi-asserted-by":"publisher","first-page":"e0104","DOI":"10.1097\/HC9.0000000000000104","volume":"7","author":"D Ito","year":"2023","unstructured":"Ito, D. et al. Spermidine enhances the efficacy of adjuvant in HBV vaccination in mice. Hepatol. Commun. 7, e0104 (2023).","journal-title":"Hepatol. Commun."},{"key":"74006_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60894-z","volume":"16","author":"M Huang","year":"2025","unstructured":"Huang, M. et al. Hepatitis B virus promotes liver cancer by modulating the immune response to environmental carcinogens. Nat. Commun. 16, 5360 (2025).","journal-title":"Nat. Commun."},{"key":"74006_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/hep.26654","volume":"59","author":"S Lv","year":"2014","unstructured":"Lv, S. et al. Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection. Hepatology 59, 385\u2013394 (2014).","journal-title":"Hepatology"},{"key":"74006_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi1572","volume":"6","author":"F Andreata","year":"2024","unstructured":"Andreata, F. et al. CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus. Sci. Transl. Med. 6, eadi1572 (2024).","journal-title":"Sci. Transl. Med."},{"key":"74006_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41577-024-01097-3","volume":"24","author":"R Thimme","year":"2024","unstructured":"Thimme, R., Bertoletti, A. & Iannacone, M. Beyond exhaustion: the unique characteristics of CD8(+) T cell dysfunction in chronic HBV infection. Nat. Rev. Immunol. 24, 775\u2013776 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"74006_CR7","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/s41590-024-01928-4","volume":"25","author":"K Heim","year":"2024","unstructured":"Heim, K. et al. Attenuated effector T cells are linked to control of chronic HBV infection. Nat. Immunol. 25, 1650\u20131662 (2024).","journal-title":"Nat. Immunol."},{"key":"74006_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37, 457\u2013495 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"74006_CR9","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jhep.2010.12.031","volume":"54","author":"ML Michel","year":"2011","unstructured":"Michel, M. L., Deng, Q. & Mancini-Bourgine, M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J. Hepatol. 54, 1286\u20131296 (2011).","journal-title":"J. Hepatol."},{"key":"74006_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.35","volume":"4","author":"MF Yuen","year":"2018","unstructured":"Yuen, M. F. et al. Hepatitis B virus infection. Nat. Rev. Dis. Primers 4, 18035 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"74006_CR11","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/cmi.2015.64","volume":"13","author":"X Wang","year":"2016","unstructured":"Wang, X. et al. Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice. Cell. Mol. Immunol. 13, 850\u2013861 (2016).","journal-title":"Cell. Mol. Immunol."},{"key":"74006_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/cei.13614","volume":"205","author":"T Cargill","year":"2021","unstructured":"Cargill, T. & Barnes, E. Therapeutic vaccination for treatment of chronic hepatitis B. Clin. Exp. Immunol. 205, 106\u2013118 (2021).","journal-title":"Clin. Exp. Immunol."},{"key":"74006_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","volume":"22","author":"M Iannacone","year":"2022","unstructured":"Iannacone, M. & Guidotti, L. G. Immunobiology and pathogenesis of hepatitis B virus infection. Nat. Rev. Immunol. 22, 19\u201332 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"74006_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3390\/pharmaceutics17020211","volume":"17","author":"S Liu","year":"2025","unstructured":"Liu, S. et al. A multivalent mRNA therapeutic vaccine exhibits breakthroughs in immune tolerance and virological suppression of HBV by stably presenting the pre-S antigen on the cell membrane. Pharmaceutics 17, 211 (2025).","journal-title":"Pharmaceutics"},{"key":"74006_CR15","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1126\/science.adp1453","volume":"385","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. Inherent symmetry and flexibility in hepatitis B virus subviral particles. Science 385, 1217\u20131224 (2024).","journal-title":"Science"},{"key":"74006_CR16","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1136\/gutjnl-2022-327059","volume":"72","author":"CY Meng","year":"2023","unstructured":"Meng, C. Y. et al. Engineered anti-PDL1 with IFN\u03b1 targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut 72, 1544\u20131554 (2023).","journal-title":"Gut"},{"key":"74006_CR17","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/hep.29239","volume":"66","author":"Y Bian","year":"2017","unstructured":"Bian, Y. et al. Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. Hepatology 66, 1067\u20131082 (2017).","journal-title":"Hepatology"},{"key":"74006_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12929-020-00662-x","volume":"27","author":"JH Horng","year":"2020","unstructured":"Horng, J. H. et al. HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice. J. Biomed. Sci. 27, 70 (2020).","journal-title":"J. Biomed. Sci."},{"key":"74006_CR19","doi-asserted-by":"publisher","first-page":"100295","DOI":"10.1016\/j.jhepr.2021.100295","volume":"3","author":"R Boudewijns","year":"2021","unstructured":"Boudewijns, R., Ma, J., Neyts, J. & Dallmeier, K. A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice. JHEP Rep. 3, 100295 (2021).","journal-title":"JHEP Rep."},{"key":"74006_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMra2211764","volume":"388","author":"G Dusheiko","year":"2023","unstructured":"Dusheiko, G., Agarwal, K. & Maini, M. K. New approaches to chronic hepatitis B. New Engl. J. Med. 388, 55\u201369 (2023).","journal-title":"New Engl. J. Med."},{"key":"74006_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80594-6","volume":"11","author":"S Kadelka","year":"2021","unstructured":"Kadelka, S., Dahari, H. & Ciupe, S. M. Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection. Sci. Rep. 11, 200 (2021).","journal-title":"Sci. Rep."},{"key":"74006_CR22","doi-asserted-by":"publisher","first-page":"e1000986","DOI":"10.1371\/journal.ppat.1000986","volume":"6","author":"H Wang","year":"2010","unstructured":"Wang, H. & Ryu, W. S. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog 6, e1000986 (2010).","journal-title":"PLoS Pathog"},{"key":"74006_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52940-z","volume":"15","author":"RA Leonard","year":"2024","unstructured":"Leonard, R. A. et al. Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA. Nat. Commun. 15, 8712 (2024).","journal-title":"Nat. Commun."},{"key":"74006_CR24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41565-020-0648-y","volume":"15","author":"W Wang","year":"2020","unstructured":"Wang, W. et al. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nat. Nanotechnol. 15, 406\u2013416 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"74006_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cmi.2013.43","volume":"11","author":"D Yang","year":"2014","unstructured":"Yang, D. et al. A mouse model for HBV immunotolerance and immunotherapy. Cell. Mol. Immunol. 11, 71\u201378 (2014).","journal-title":"Cell. Mol. Immunol."},{"key":"74006_CR26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/hep.26668","volume":"59","author":"L Xu","year":"2014","unstructured":"Xu, L., Yin, W., Sun, R., Wei, H. & Tian, Z. Kupffer cell-derived IL-10 plays a key role in maintaining humoral immune tolerance in hepatitis B virus-persistent mice. Hepatology 59, 443\u2013452 (2014).","journal-title":"Hepatology"},{"key":"74006_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43078-5","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Interferon stimulated immune profile changes in a humanized mouse model of HBV infection. Nat. Commun. 14, 7393 (2023).","journal-title":"Nat. Commun."},{"key":"74006_CR28","first-page":"357","volume":"70","author":"RS Wijaya","year":"2021","unstructured":"Wijaya, R. S. et al. HBV vaccination and HBV infection induces HBV-specific natural killer cell memory. Gut 70, 357\u2013369 (2021).","journal-title":"Gut"},{"key":"74006_CR29","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1002\/eji.200324125","volume":"33","author":"R Schirmbeck","year":"2003","unstructured":"Schirmbeck, R., B\u00f6hm, W., Fissolo, N., Melber, K. & Reimann, J. Different immunogenicity of H-2 Kb-restricted epitopes in natural variants of the hepatitis B surface antigen. Eur. J. Immunol. 33, 2429\u20132438 (2003).","journal-title":"Eur. J. Immunol."},{"key":"74006_CR30","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41590-025-02199-3","volume":"26","author":"V Venzin","year":"2025","unstructured":"Venzin, V. et al. CD4(+) T cells license Kupffer cells to reverse CD8(+) T cell dysfunction induced by hepatocellular priming. Nat. Immunol. 26, 1352\u20131366 (2025).","journal-title":"Nat. Immunol."},{"key":"74006_CR31","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41586-024-07630-7","volume":"631","author":"M Bosch","year":"2024","unstructured":"Bosch, M. et al. A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection. Nature 631, 867\u2013875 (2024).","journal-title":"Nature"},{"key":"74006_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2007.10.049","volume":"579","author":"V Tayal","year":"2008","unstructured":"Tayal, V. & Kalra, B. S. Cytokines and anti-cytokines as therapeutics\u2014an update. Eur. J. Pharmacol. 579, 1\u201312 (2008).","journal-title":"Eur. J. Pharmacol."},{"key":"74006_CR33","doi-asserted-by":"publisher","first-page":"156028","DOI":"10.1016\/j.phymed.2024.156028","volume":"135","author":"S Beigoli","year":"2024","unstructured":"Beigoli, S. & Boskabady, M. H. The molecular basis of the immunomodulatory effects of natural products: a comprehensive review. Phytomedicine 135, 156028 (2024).","journal-title":"Phytomedicine"},{"key":"74006_CR34","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/hep.31282","volume":"73","author":"J Chen","year":"2021","unstructured":"Chen, J. et al. Functional comparison of interferon-\u03b1 subtypes reveals potent hepatitis B virus suppression by a concerted action of interferon-\u03b1 and interferon-\u03b3 signaling. Hepatology 73, 486\u2013502 (2021).","journal-title":"Hepatology"},{"key":"74006_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/liv.12749","volume":"35","author":"C Ferrari","year":"2015","unstructured":"Ferrari, C. HBV and the immune response. Liver Int. 35, 121\u2013128 (2015).","journal-title":"Liver Int."},{"key":"74006_CR36","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1126\/science.2408336","volume":"228","author":"DR Milich","year":"1985","unstructured":"Milich, D. R. et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 228, 1195\u20131199 (1985).","journal-title":"Science"},{"key":"74006_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00430-014-0374-x","volume":"204","author":"D Shouval","year":"2015","unstructured":"Shouval, D., Roggendorf, H. & Roggendorf, M. Enhanced immune response to hepatitis B vaccination through immunization with a pre-S1\/pre-S2\/S vaccine. Med. Microbiol. Immunol. 204, 57\u201368 (2015).","journal-title":"Med. Microbiol. Immunol."},{"key":"74006_CR38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4049\/jimmunol.137.1.315","volume":"137","author":"DR Milich","year":"1986","unstructured":"Milich, D. R., McLachlan, A., Chisari, F. V., Kent, S. B. & Thorton, G. B. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg. J. Immunol. 137, 315\u2013322 (1986).","journal-title":"J. Immunol."},{"key":"74006_CR39","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.4049\/jimmunol.138.12.4457","volume":"138","author":"DR Milich","year":"1987","unstructured":"Milich, D. R., McLachlan, A., Moriarty, A. & Thornton, G. B. A single 10-residue pre-S(1) peptide can prime T cell help for antibody production to multiple epitopes within the pre-S(1), pre-S(2), and S regions of HBsAg. J. Immunol. 138, 4457\u20134465 (1987).","journal-title":"J. Immunol."},{"key":"74006_CR40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jhep.2010.10.025","volume":"55","author":"AJ Gehring","year":"2011","unstructured":"Gehring, A. J. et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J. Hepatol. 55, 103\u2013110 (2011).","journal-title":"J. Hepatol."},{"key":"74006_CR41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/21645515.2019.1689745","volume":"16","author":"DC Whitacre","year":"2020","unstructured":"Whitacre, D. C. et al. Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance. Hum. Vaccin. Immunother. 16, 251\u2013268 (2020).","journal-title":"Hum. Vaccin. Immunother."},{"key":"74006_CR42","doi-asserted-by":"publisher","first-page":"100361","DOI":"10.1016\/j.jhepr.2021.100361","volume":"3","author":"H Ma","year":"2021","unstructured":"Ma, H. et al. Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib\/IIa study. JHEP Rep. 3, 100361 (2021).","journal-title":"JHEP Rep."},{"key":"74006_CR43","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1128\/AAC.00276-09","volume":"53","author":"PT Hoa","year":"2009","unstructured":"Hoa, P. T. et al. Randomized controlled study investigating viral suppression and serological response following pre-S1\/pre-S2\/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob. Agents Chemother. 53, 5134\u20135140 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"74006_CR44","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.vaccine.2015.12.060","volume":"34","author":"S Backes","year":"2016","unstructured":"Backes, S. et al. Protein-prime\/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice. Vaccine 34, 923\u2013932 (2016).","journal-title":"Vaccine"},{"key":"74006_CR45","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1053\/j.gastro.2020.01.032","volume":"158","author":"T Michler","year":"2020","unstructured":"Michler, T. et al. Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice. Gastroenterology 158, 1762\u20131775 (2020).","journal-title":"Gastroenterology"},{"key":"74006_CR46","doi-asserted-by":"publisher","first-page":"100603","DOI":"10.1016\/j.jhepr.2022.100603","volume":"5","author":"J Sacherl","year":"2023","unstructured":"Sacherl, J. et al. Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance. JHEP Rep. 5, 100603 (2023).","journal-title":"JHEP Rep."},{"key":"74006_CR47","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jhep.2022.12.013","volume":"78","author":"J Su","year":"2023","unstructured":"Su, J. et al. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models. J. Hepatol. 78, 717\u2013730 (2023).","journal-title":"J. Hepatol."},{"key":"74006_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102641","volume":"36","author":"AD Kosinska","year":"2025","unstructured":"Kosinska, A. D. et al. MVA-HBVac-A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination. Mol. Ther. Nucleic Acids 36, 102641 (2025).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"74006_CR49","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41575-019-0196-9","volume":"16","author":"MK Maini","year":"2019","unstructured":"Maini, M. K. & Burton, A. R. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat. Rev. Gastroenterol. Hepatol. 16, 662\u2013675 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"74006_CR50","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1084\/jem.20151218","volume":"213","author":"Z Zeng","year":"2016","unstructured":"Zeng, Z. et al. Interferon-\u03b3 facilitates hepatic antiviral T cell retention for the maintenance of liver-induced systemic tolerance. J. Exp. Med. 213, 1079\u20131093 (2016).","journal-title":"J. Exp. Med."},{"key":"74006_CR51","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41392-021-00776-0","volume":"6","author":"D Wang","year":"2021","unstructured":"Wang, D. et al. Restoration of HBV-specific CD8(+) T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-\u03b1 therapy. Signal Transduct. Target. Ther. 6, 376 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"74006_CR52","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1016\/j.cell.2024.05.038","volume":"187","author":"F Andreata","year":"2024","unstructured":"Andreata, F. et al. Therapeutic potential of co-signaling receptor modulation in hepatitis B. Cell 187, 4078\u20134094 (2024).","journal-title":"Cell"},{"key":"74006_CR53","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01612-22","volume":"13","author":"B Chen","year":"2022","unstructured":"Chen, B. et al. A single dose of anti-HBsAg antibody-encoding mRNA-LNPs suppressed HBsAg expression: a potential cure of chronic hepatitis B virus infection. mBio 13, e0161222 (2022).","journal-title":"mBio"},{"key":"74006_CR54","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41392-024-01871-8","volume":"9","author":"W Zai","year":"2024","unstructured":"Zai, W. et al. Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection. Signal Transduct. Target. Ther. 9, 150 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"74006_CR55","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000080872","volume":"47","author":"H Norder","year":"2004","unstructured":"Norder, H. et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 47, 289\u2013309 (2004).","journal-title":"Intervirology"},{"key":"74006_CR56","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.bpg.2017.04.014","volume":"31","author":"M Dandri","year":"2017","unstructured":"Dandri, M. & Petersen, J. Animal models of HBV infection. Best Pract. Res. Clin. Gastroenterol. 31, 273\u2013279 (2017).","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"74006_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2015.06.012","volume":"121","author":"L Cheng","year":"2015","unstructured":"Cheng, L., Li, F., Bility, M. T., Murphy, C. M. & Su, L. Modeling hepatitis B virus infection, immunopathology and therapy in mice. Antiviral Res. 121, 1\u20138 (2015).","journal-title":"Antiviral Res."},{"key":"74006_CR58","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","volume":"621","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 621, 396\u2013403 (2023).","journal-title":"Nature"},{"key":"74006_CR59","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74006-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74006-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74006-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:05:21Z","timestamp":1785755121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74006-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74006"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74006-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7686"}}